Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
AUTOR(ES)
Kataoka, A
RESUMO
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=489823Documentos Relacionados
- Multimodality evoked potentials in HTLV-I associated myelopathy.
- MRI-pathological correlate of brain lesions in a necropsy case of HTLV-I associated myelopathy.
- Development of HTLV-I associated myelopathy (HAM) in a seroconverted patient for antibody to HTLV-I.
- Cardiomyopathy associated with high-dose interleukin-2 therapy.
- HLA profile and HTLV-I associated myelopathy (HAM/TSP) in Natal, South Africa.